Jan 24, 2023
Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome
Minato-ku, Tokyo, Japan, January 24 2023 — Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, announced the initiation of a phase 3 clinical study of pitolisant (), a histamine H3 receptor antagonist/inverse agonist in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS), in Japan
This trial is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study (Part 1) and a subsequent multi-center, open-label, long-term extension study (Part 2) to assess the safety and efficacy of pitolisant in the Japanese patient population. ―― Additional study details can be found here: https://jrct.niph.go.jp/latest-detail/jRCT2031220501
Aculys has an exclusive license to develop and commercialize pitolisant in Japan. Pitolisant, developed by Paris-based Bioprojet, was approved by the European Medicines Agency (EMA) for the treatment of “excessive daytime sleepiness associated with obstructive sleep apnea syndrome (OSAS)” in 2021, and has since been available in the clinical setting.
OSAS is characterized by an interruption of proper breathing due to the narrowing or obstruction of the upper airway during sleep. Typical symptoms include loud snoring, daytime sleepiness, insomnia, sense of insufficient deep sleep, and systemic fatigue. If OSAS is not properly treated, in the medium- to long-term, patients may develop complications such as diabetes, depression, hypertension, arteriosclerosis, and other cardiovascular conditions1,2.
Continuous Positive Airway Pressure (CPAP) is considered the standard treatment in OSAS and is used to mitigate the narrowing and obstruction of the upper airway and is known to contribute to improving various OSAS symptoms and patients’ quality of life (QOL). However, some patients reportedly experience persistent excessive daytime sleepiness despite appropriate basic treatment3, and excessive daytime sleepiness is considered a risk factor for impact on labor productivity, reduced quality of life, and accidents such as traffic accidents4, so new treatment options are needed.
Aculys Pharma is committed to bringing this drug to patients with OSAS in Japan as early as possible and aims to help achieve a society where people with OSAS and their family members live their lives to the fullest potential.
About Pitolisant
Pitolisant is an antagonist/inverse agonist that selectively binds to the histamine H3 receptor, an autoreceptor located in the presynaptic region of the histamine-containing neurons in the human brain that plays a critical role in regulating sleep and wake rhythm. The drug was created by Paris-based Bioprojet and was approved by the European Medicines Agency (EMA) for the treatment of “narcolepsy with or without cataplexy” in 2016 and for the treatment of “excessive daytime sleepiness associated with obstructive sleep apnea syndrome (OSAS)” in 2021. In the United States, the drug was approved by the Food and Drug Administration (FDA) for the treatment of “excessive daytime sleepiness associated with narcolepsy” in 2019 and “cataplexy associated with narcolepsy” in 2020.
About Aculys Pharma, Inc.
Aculys Pharma is a clinical stage biopharmaceutical company focused on the commercialization of neurology innovations for patients in Japan. Aculys was formed in 2021 as a catalyst to neurology innovation access. We are committed to shortening the drug lag in Japan by developing and commercializing novel CNS treatments; applying blockchain and AI technologies to increase speed to market; and providing services to improve medical care for patients, their families, healthcare professionals, and society.
Company name: Aculys Pharma, Inc.
Address: 2-14-4 KitaAoyama, Minato-ku,Tokyo, Japan
Representative: Kazunari Tsunaba
Established: January 2021
URL: https://aculys.com
Information concerning pharmaceutical products (compound under development) contained herein is not intended as advertising or as medical advice but intended for disclosure of management information.
References:
1. The Japanese Circulation Society. JCS Joint Working Groups for Guidelines for Diagnosis and Treatment of Cardiovascular Diseases (2008-2009 joint research team report) Guidelines for Diagnosis and Treatment of Sleep Disordered Breathing in Cardiovascular Disease2. Clinical Practice Guidelines for Sleep Apnea Syndrome (SAS) 2020 (edited by committee preparing Clinical Practice Guidelines for Sleep Apnea Syndrome (SAS)3. Update on Persistent Excessive Daytime Sleepiness in OSA; Chest . 2020 Aug;158(2):776-786.4. The economic and societal burden of excessive daytime sleepiness in patients with obstructive sleep apnea. Sleep Med Rev. 2020 Jun;51:101275.
